Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary
aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also
anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been
attributed to glucocorticoids related to both the average dose and cumulative duration of
use.
Deflazacort is a oxazoline steroid with demonstrated anti-inflammatory and immunosuppressant
effects. The novel structural characteristic of deflazacort is associated with substantial
lack of sodium-retaining activity, lower interference with carbohydrate metabolism and
calcium metabolism in comparison with older glucocorticoids such as prednisolone. The
investigators hypothesize that the occurrence of side-effects, primarily weight gain will be
lower with deflazacort. In this study, the investigators will compare the safety and efficacy
of deflazacort in the treatment of acute-stage ABPA complicating asthma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research